TG Therapeutics/$TGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Ticker
$TGTX
Sector
Primary listing
Employees
399
Headquarters
Website
TG Therapeutics Metrics
BasicAdvanced
$7.1bn
17.52
$2.87
1.68
-
Price and volume
Market cap
$7.1bn
Beta
1.68
52-week high
$50.60
52-week low
$25.28
Average daily volume
2.3m
Financial strength
Current ratio
5.809
Quick ratio
4.845
Long term debt to equity
128.914
Total debt to equity
129.226
Interest coverage (TTM)
5.41%
Profitability
EBITDA (TTM)
149.58
Gross margin (TTM)
83.05%
Net profit margin (TTM)
65.95%
Operating margin (TTM)
21.35%
Effective tax rate (TTM)
-277.72%
Revenue per employee (TTM)
$1,760,000
Management effectiveness
Return on assets (TTM)
8.55%
Return on equity (TTM)
112.60%
Valuation
Price to earnings (TTM)
17.521
Price to revenue (TTM)
10.325
Price to book
12.23
Price to tangible book (TTM)
12.23
Price to free cash flow (TTM)
-509.548
Free cash flow yield (TTM)
-0.20%
Free cash flow per share (TTM)
-0.099
Growth
Revenue change (TTM)
81.26%
Earnings per share change (TTM)
1,105.51%
3-year revenue growth (CAGR)
333.92%
10-year revenue growth (CAGR)
132.40%
3-year earnings per share growth (CAGR)
32.60%
10-year earnings per share growth (CAGR)
8.19%
What the Analysts think about TG Therapeutics
Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.
TG Therapeutics Financial Performance
Revenues and expenses
TG Therapeutics Earnings Performance
Company profitability
TG Therapeutics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs